UBS Group’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-64,879
| Closed | -$293K | – | 10600 |
|
|
2025
Q4 | $293K | Sell |
64,879
-336,390
| -84% | -$1.72M | ﹤0.01% | 6373 |
|
|
2025
Q3 | $2.16M | Buy |
401,269
+159,179
| +66% | +$861K | ﹤0.01% | 4870 |
|
|
2025
Q2 | $1.31M | Sell |
242,090
-601,103
| -71% | -$2.38M | ﹤0.01% | 5204 |
|
|
2025
Q1 | $2.34M | Buy |
843,193
+266,296
| +46% | +$926K | ﹤0.01% | 4576 |
|
|
2024
Q4 | $1.97M | Buy |
576,897
+517,223
| +867% | +$1.49M | ﹤0.01% | 4728 |
|
|
2024
Q3 | $175K | Sell |
59,674
-53,298
| -47% | -$176K | ﹤0.01% | 5970 |
|
|
2024
Q2 | $384K | Sell |
112,972
-591,219
| -84% | -$1.93M | ﹤0.01% | 5202 |
|
|
2024
Q1 | $2.13M | Buy |
704,191
+572,319
| +434% | +$2.01M | ﹤0.01% | 3882 |
|
|
2023
Q4 | $555K | Buy |
131,872
+56,316
| +75% | +$305K | ﹤0.01% | 5025 |
|
|
2023
Q3 | $516K | Sell |
75,556
-13,200
| -15% | -$117K | ﹤0.01% | 4625 |
|
|
2023
Q2 | $925K | Sell |
88,756
-79,512
| -47% | -$711K | ﹤0.01% | 4325 |
|
|
2023
Q1 | $1.17M | Buy |
168,268
+81,964
| +95% | +$715K | ﹤0.01% | 3971 |
|
|
2022
Q4 | $520K | Buy |
86,304
+26,103
| +43% | +$193K | ﹤0.01% | 4662 |
|
|
2022
Q3 | $475K | Buy |
60,201
+30,525
| +103% | +$356K | ﹤0.01% | 4382 |
|
|
2022
Q2 | $403K | Buy |
29,676
+24,383
| +461% | +$403K | ﹤0.01% | 4409 |
|
|
2022
Q1 | $104K | Buy |
5,293
+103
| +2% | +$2.06K | ﹤0.01% | 5886 |
|
|
2021
Q4 | $178K | Buy |
5,190
+1,646
| +46% | +$66.2K | ﹤0.01% | 5799 |
|
|
2021
Q3 | $193K | Sell |
3,544
-110,087
| -97% | -$6.63M | ﹤0.01% | 5346 |
|
|
2021
Q2 | $8.35M | Buy |
113,631
+109,646
| +2,751% | +$11M | ﹤0.01% | 2199 |
|
|
2021
Q1 | $364K | Buy |
3,985
+424
| +12% | +$41.1K | ﹤0.01% | 5090 |
|
|
2020
Q4 | $288K | Buy |
3,561
+2,346
| +193% | +$180K | ﹤0.01% | 4995 |
|
|
2020
Q3 | $57K | Buy |
+1,215
| New | +$67.8K | ﹤0.01% | 5549 |
|
UBS Group's CVAC Position: Q1 2026 in Review
UBS Group sold out of CureVac (CVAC) in Q1 2026, closing a stake of 64,879 shares — an estimated $293K sold.
UBS Group first reported a position in CVAC in Q3 2020 and held it in 22 quarters. The position peaked at $8.35M in Q2 2021. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- UBS Group reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 64,879 CureVac shares in Q1 2026, an estimated $293K.
- UBS Group first reported a position in CureVac in Q3 2020 and held it in 22 quarters.
- UBS Group's CureVac position peaked at $8.35M in Q2 2021.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.